Header Logo

Connection

LINGEGOWDA SELANERE MANGALA to Animals

Back to Details
This is a "connection" page, showing publications LINGEGOWDA SELANERE MANGALA has written about Animals.
LINGEGOWDA SELANERE MANGALA
Connection Strength
0.585
Animals
  1. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2021; 2372:157-168.
    View in: PubMed
    Score: 0.032
  2. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.
    View in: PubMed
    Score: 0.022
  3. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
    View in: PubMed
    Score: 0.014
  4. Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.
    View in: PubMed
    Score: 0.014
  5. Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci. 2006 Jan 01; 11:173-85.
    View in: PubMed
    Score: 0.011
  6. Tissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res. 2005; 38:125-38.
    View in: PubMed
    Score: 0.011
  7. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
    View in: PubMed
    Score: 0.010
  8. Enhancing oral delivery of plant-derived vesicles for colitis. J Control Release. 2023 05; 357:472-483.
    View in: PubMed
    Score: 0.009
  9. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).
    View in: PubMed
    Score: 0.009
  10. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther. 2022 11 02; 30(11):3462-3476.
    View in: PubMed
    Score: 0.009
  11. Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. J Cancer Res Clin Oncol. 2022 Apr; 148(4):803-821.
    View in: PubMed
    Score: 0.009
  12. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
    View in: PubMed
    Score: 0.008
  13. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.
    View in: PubMed
    Score: 0.008
  14. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.
    View in: PubMed
    Score: 0.008
  15. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 2021 04 30; 11(1):9362.
    View in: PubMed
    Score: 0.008
  16. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021 02 09; 34(6):108726.
    View in: PubMed
    Score: 0.008
  17. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.
    View in: PubMed
    Score: 0.008
  18. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep. 2019 12 24; 29(13):4389-4406.e10.
    View in: PubMed
    Score: 0.008
  19. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest. 2019 12 02; 129(12):5343-5356.
    View in: PubMed
    Score: 0.007
  20. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. 2019 08; 38(33):6095-6108.
    View in: PubMed
    Score: 0.007
  21. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer. 2019 07 15; 125(14):2409-2422.
    View in: PubMed
    Score: 0.007
  22. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.
    View in: PubMed
    Score: 0.007
  23. Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene. 2019 06; 38(26):5191-5210.
    View in: PubMed
    Score: 0.007
  24. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.
    View in: PubMed
    Score: 0.007
  25. Bone protection by inhibition of microRNA-182. Nat Commun. 2018 10 05; 9(1):4108.
    View in: PubMed
    Score: 0.007
  26. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.
    View in: PubMed
    Score: 0.007
  27. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018 10 15; 24(20):5072-5084.
    View in: PubMed
    Score: 0.007
  28. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242.
    View in: PubMed
    Score: 0.007
  29. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018 03; 37(1):107-124.
    View in: PubMed
    Score: 0.007
  30. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun. 2018 02 02; 9(1):476.
    View in: PubMed
    Score: 0.007
  31. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 02 01; 128(2):589-606.
    View in: PubMed
    Score: 0.007
  32. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.
    View in: PubMed
    Score: 0.007
  33. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795.
    View in: PubMed
    Score: 0.007
  34. MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res. 2018 01 01; 78(1):64-74.
    View in: PubMed
    Score: 0.007
  35. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci. 2018 01; 86:65-71.
    View in: PubMed
    Score: 0.007
  36. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515.
    View in: PubMed
    Score: 0.006
  37. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
    View in: PubMed
    Score: 0.006
  38. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017 08 21; 8(1):310.
    View in: PubMed
    Score: 0.006
  39. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.006
  40. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget. 2017 Apr 18; 8(16):27380-27392.
    View in: PubMed
    Score: 0.006
  41. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY). 2016 12 16; 8(12):3507-3519.
    View in: PubMed
    Score: 0.006
  42. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016 11 08; 24(5):685-700.
    View in: PubMed
    Score: 0.006
  43. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep. 2016 11 01; 17(6):1621-1631.
    View in: PubMed
    Score: 0.006
  44. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. 2017 02 16; 36(7):912-921.
    View in: PubMed
    Score: 0.006
  45. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. 2016 08 08; 30(2):273-289.
    View in: PubMed
    Score: 0.006
  46. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888.
    View in: PubMed
    Score: 0.006
  47. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 2016 Apr 12; 7(15):20825-39.
    View in: PubMed
    Score: 0.006
  48. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 05 02; 126(5):1885-96.
    View in: PubMed
    Score: 0.006
  49. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.006
  50. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.
    View in: PubMed
    Score: 0.006
  51. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. 2016 08 18; 35(33):4312-20.
    View in: PubMed
    Score: 0.006
  52. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol. 2016; 1402:189-197.
    View in: PubMed
    Score: 0.006
  53. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2016 Jan; 63(1):159-72.
    View in: PubMed
    Score: 0.006
  54. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.
    View in: PubMed
    Score: 0.006
  55. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77.
    View in: PubMed
    Score: 0.006
  56. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 2015 Jul; 107(7).
    View in: PubMed
    Score: 0.005
  57. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.
    View in: PubMed
    Score: 0.005
  58. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.
    View in: PubMed
    Score: 0.005
  59. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.
    View in: PubMed
    Score: 0.005
  60. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014 Aug 28; 512(7515):431-5.
    View in: PubMed
    Score: 0.005
  61. Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.
    View in: PubMed
    Score: 0.005
  62. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.005
  63. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.
    View in: PubMed
    Score: 0.005
  64. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.005
  65. Src activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.
    View in: PubMed
    Score: 0.005
  66. Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun 01; 17(11):3649-59.
    View in: PubMed
    Score: 0.004
  67. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011 Apr; 13(4):309-19.
    View in: PubMed
    Score: 0.004
  68. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.
    View in: PubMed
    Score: 0.004
  69. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
    View in: PubMed
    Score: 0.004
  70. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.
    View in: PubMed
    Score: 0.004
  71. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22.
    View in: PubMed
    Score: 0.004
  72. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.
    View in: PubMed
    Score: 0.004
  73. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70.
    View in: PubMed
    Score: 0.004
  74. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.
    View in: PubMed
    Score: 0.004
  75. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.
    View in: PubMed
    Score: 0.004
  76. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.
    View in: PubMed
    Score: 0.004
  77. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603.
    View in: PubMed
    Score: 0.004
  78. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
    View in: PubMed
    Score: 0.004
  79. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.004
  80. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009 May 01; 15(9):2971-8.
    View in: PubMed
    Score: 0.004
  81. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr 15; 15(8):2695-702.
    View in: PubMed
    Score: 0.004
  82. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53.
    View in: PubMed
    Score: 0.004
  83. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200.
    View in: PubMed
    Score: 0.003
  84. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.
    View in: PubMed
    Score: 0.003
  85. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.
    View in: PubMed
    Score: 0.003
  86. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.
    View in: PubMed
    Score: 0.003
  87. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007 Dec; 117(12):4044-54.
    View in: PubMed
    Score: 0.003
  88. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.
    View in: PubMed
    Score: 0.003
  89. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.
    View in: PubMed
    Score: 0.003
  90. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.